Taysha Gene Therapies (TSHA) Capital Expenditures (2020 - 2026)

Taysha Gene Therapies has reported Capital Expenditures for 7 years, with the latest figure at $24000.0 in Q1 2026.

• Quarterly Capital Expenditures rose 4.35% year-over-year to $24000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $739000.0 (up 187.55% YoY) and the FY2025 annual result came in at $738000.0, up 97.33% from the prior year.
• Capital Expenditures eased to $24000.0 in Q1 2026 per TSHA's latest filing, from $713000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $20.6 million in Q4 2022 and troughed at -$3.4 million in Q3 2023.
• A 5-year average of $1.5 million and a median of $24000.0 in 2026 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2023 and 2025: Capital Expenditures plunged 4869.57% in 2023, then soared 35750.0% in 2025.
• Over 5 years, Capital Expenditures stood at $20.6 million in 2022, then tumbled by 83.25% to $3.4 million in 2023, then slumped by 100.06% to -$2000.0 in 2024, then jumped by 35750.0% to $713000.0 in 2025, then plunged by 96.63% to $24000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $24000.0, $713000.0, and -$386000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.